| Overview |
| bs-2211R-APC-Cy7 |
| CD80 Polyclonal Antibody, APC-Cy7 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat |
| Specifications |
| APC-Cy7 |
| Rabbit |
| KLH conjugated synthetic peptide derived from rat CD80 |
| 251-321/321 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 25408 |
| G3V671 |
| Cell membrane |
| B7-1; Activation B7 1 antigen; Activation B71 antigen; B lymphocyte activation antigen B7; B7; BB1; CD 80; CD28 antigen ligand 1 B7 1 antigen; CD28 antigen ligand 1 B71 antigen; CD28LG; CD28LG1; CD80 antigen; CD80 antigen precursor;CD80 molecule; Costimulatory factor CD80; CTLA 4 counter receptor B7.1; CTLA-4 counter-receptor B7.1; LAB 7; LAB7; T lymphocyte activation antigen CD80; CD80_MOUSE. |
| CD80 is a member of the Ig superfamily and serves as the ligand for two T cell molecules, CD28 and CTLA4. Interactions between CD28 and CD80 on activated B cells result in enhanced T cell activation. CD80 is rapidly induced on the surface of in vitro activated B cells, Epstein Barr Virus (EBV) transformed B cell lines, Burkitts lymphoma cell lines, freshly isolated follicular B lymphoma cells, T cells, and monocytes. It is also expressed at high levels in dendritic cells. It reacts weakly with a small proportion of non activated normal B cells and with HTLV1 infected T cells. CD80 does not react with peripheral monocytes, resting and activated normal T cells, T cell lines and T cell clones, nor with myelomonocytic cell lines. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz